A comparative study on the effects of a monophasic pill containing desogestrel plus 20 μg ethinylestradiol, a triphasic combination containing levonorgestrel and a monophasic combination containing gestodene on coagulatory factors

Contraception

Volumn 43, Issue 1, 1991, Pages 23-31

  Melis, G B ^c   Fruzzetti, F ^a   Nicoletti, I ^a   Ricci, C ^a   Lammers, P ^b   Atsma, W J ^b   Fioretti, P ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NV ORGANON   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ETHINYLESTRADIOL; FIBRINOGEN; FIBRINOPEPTIDE A; GESTODENE; LEVONORGESTREL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE;

BIOLOGY; BLOOD COAGULATION EFFECTS; COMPARATIVE STUDIES; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--SIDE EFFECTS; CONTRACEPTIVE AGENTS, FEMALE--SIDE EFFECTS; CONTRACEPTIVE AGENTS--SIDE EFFECTS; CONTRACEPTIVE METHODS--SIDE EFFECTS; CONTRACEPTIVE USAGE; DATA ANALYSIS; DATA COLLECTION; DEVELOPED COUNTRIES; ETHINYL ESTRADIOL--SIDE EFFECTS; EUROPE; EXAMINATIONS AND DIAGNOSES; FAMILY PLANNING; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; HOMEOSTASIS; ITALY; LABORATORY EXAMINATIONS AND DIAGNOSES; MEDITERRANEAN COUNTRIES; METHOD ACCEPTABILITY; ORAL CONTRACEPTIVES--SIDE EFFECTS; PHYSIOLOGY; RESEARCH METHODOLOGY; SOUTHERN EUROPE; STUDIES;

ADULT; ANALYSIS OF VARIANCE; BLOOD COAGULATION FACTORS; COMPARATIVE STUDY; CONTRACEPTIVES, ORAL, COMBINED; DESOGESTREL; ETHINYL ESTRADIOL; FEMALE; FIBRINOGEN; FIBRINOPEPTIDE A; HUMAN; LEVONORGESTREL; LONGITUDINAL STUDIES; NORGESTREL; NORPREGNENES; PROGESTATIONAL HORMONES, SYNTHETIC; RANDOM ALLOCATION;

EID: 0025966622     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/0010-7824(91)90123-W     Document Type: Article

References (20)

1. Oral contraceptive and cardiovascular disease
2. Oral contraceptives and cardiovascular disease
3. Further analysis of mortality in oral contraceptive users
4. Oral contraceptives, lipids and cardiovascular disease
5. Progestogen effects and their relationship to lipoprotein changes
6. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoprotein
7. Lipids, clotting factors and diabetes: endogenous risk factors for cardiovascular disease
8. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-μg oestrogen preparations
9. Fibrinopeptide A plasma levels during low-estrogen oral contraceptive treatment
10. AT III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women
11. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs
12. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content
13. Metabolic effects of three new low-dose pills: a six-month experience
14. Clinical and metabolic effects of a pill containing 30 meg ethinylestradiol plus 75 mcg gestodene
15. Oral contraceptives and venous thromboembolic disease the effect of the oestrogen dose
16. Effect of a monophasic pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel on coagulatory factors
17. Measurement of Fibrinopeptide A in human blood
18. Potential use of Fibrinopeptide A measurements in the diagnosis and management of thrombosis
19. Radioimmunoassay of Fibrinopeptide A. Clinical applications
20. Clinical relevance of antithrombin III